August 17, 2020
A key health ministry advisory panel will discuss on August 27 whether to recommend approval for Kaken Pharmaceutical’s axillary hyperhidrosis treatment sofpironium bromide and Japan Tobacco’s renal anemia treatment enarodustat. If all goes well, they could land approval next month...read more